Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMC6U93)

• Drug Name: Torin2 Drug Info
• Synonyms: Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE
• Cross-matching ID:
  PubChem CID: 51358113
  ChEBI ID: CHEMBL90682
  CAS Number: CAS 1223001-51-1
  TTD Drug ID: D2B7WM

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
SNARE interactions in vesicular transport	1.88	4.70e-2	19/33 (57.58%)	STX1A;STX7;STX16;...
Glyoxylate and dicarboxylate metabolism	-1.61	4.47e-2	23/30 (76.67%)	AGXT;ACO1;MDH1;...
Aldosterone-regulated sodium reabsorption	-1.63	3.62e-2	34/37 (91.89%)	ATP1A2;ATP1A3;HSD11B2;...
Chemical carcinogenesis	-1.63	3.75e-2	186/281 (66.19%)	PTGES3;UGT2B15;UGT2B4;...
Propanoate metabolism	-1.67	2.27e-2	30/34 (88.24%)	DBT;MLYCD;LDHA;...
Proteasome	-1.67	2.26e-2	44/46 (95.65%)	ADRM1;PSME1;PSMD8;...
Parkinson disease	-1.72	1.34e-2	176/249 (70.68%)	GNAI1;ADRM1;KLC2;...
Cysteine and methionine metabolism	-1.76	8.93e-3	43/50 (86%)	DNMT3B;LDHA;SDS;...
Pyruvate metabolism	-1.76	9.33e-3	41/47 (87.23%)	ACYP2;LDHA;ADH5;...
Prion disease	-1.76	9.78e-3	209/273 (76.56%)	ADRM1;KLC2;SDHB;...
Folate biosynthesis	-1.76	1.03e-2	23/26 (88.46%)	MOCOS;ALPG;PTS;...
Arginine and proline metabolism	-1.77	1.01e-2	39/50 (78%)	ALDH2;ALDH4A1;GOT2;...
Glycolysis / Gluconeogenesis	-1.77	9.27e-3	56/67 (83.58%)	ALDH9A1;PKM;MINPP1;...
Biosynthesis of unsaturated fatty acids	-1.81	5.28e-3	21/27 (77.78%)	ELOVL5;ACOX1;FADS1;...
Glycine, serine and threonine metabolism	-1.82	5.61e-3	31/40 (77.5%)	SDS;GAMT;BHMT;...
Fatty acid degradation	-1.83	5.99e-3	40/43 (93.02%)	CPT1A;ADH5;ADH1A;...
Butanoate metabolism	-1.84	6.42e-3	23/28 (82.14%)	OXCT1;BDH1;ACAT1;...
Pantothenate and CoA biosynthesis	-1.86	5.92e-3	14/21 (66.67%)	COASY;ALDH2;PANK3;...
Pyrimidine metabolism	-1.88	5.35e-3	40/56 (71.43%)	NME7;ENTPD1;NME1;...
Citrate cycle (TCA cycle)	-1.88	5.83e-3	30/30 (100%)	ACO1;PDHB;MDH1;...
Terpenoid backbone biosynthesis	-1.89	6.42e-3	18/22 (81.82%)	PMVK;ACAT1;HMGCS2;...
Mismatch repair	-1.90	7.13e-3	22/23 (95.65%)	RFC5;POLD1;EXO1;...
Valine, leucine and isoleucine degradation	-1.95	4.81e-3	42/48 (87.5%)	MCCC2;ACADM;OXCT1;...
Drug metabolism	-1.96	5.50e-3	78/151 (51.66%)	NME7;MAOA;TPMT;...
Oxidative phosphorylation	-1.98	4.28e-3	93/133 (69.92%)	SDHD;NDUFA7;PPA2;...
Metabolism of xenobiotics by cytochrome P450	-2.00	2.57e-3	49/77 (63.64%)	ADH5;GSTA3;ADH1A;...
Glutathione metabolism	-2.01	3.21e-3	43/57 (75.44%)	GSTA3;G6PD;HPGDS;...
Diabetic cardiomyopathy	-2.04	0.00e+0	162/203 (79.8%)	TGFBR1;SDHD;G6PD;...
DNA replication	-2.20	0.00e+0	34/36 (94.44%)	DNA2;SSBP1;POLD2;...
Steroid biosynthesis	-2.23	0.00e+0	19/20 (95%)	NSDHL;TM7SF2;LIPA;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H	Hide ▲
SK-BR-3	CVCL_0033	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H	Show ▼

Breast carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BT-20	CVCL_0178	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H	Show ▼
Hs 578T	CVCL_0332	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼